Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2023 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Third Quarter 2023 Financial Results

Raises full year 2023 adjusted operating earnings (non-GAAP)(1) guidance range to $95 million to $110 million from previous range of $75 million to $100 millionTotal revenues (GAAP) of $153.9 million...
November 07, 2023 16:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in the Jefferies London Healthcare Conference

ROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 02, 2023 07:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
October 25, 2023 16:15 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023

ROCKVILLE, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
October 16, 2023 17:34 ET | Source: Supernus Pharmaceuticals, Inc.

Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with...
October 09, 2023 16:45 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

ROCKVILLE, Md., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
September 27, 2023 16:15 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City

ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
September 09, 2023 20:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms

Topline results from Phase IV study demonstrate Qelbree is safe and well-tolerated, and significantly improved efficacy outcomes when added to a stimulant medication in pediatric patients with...
August 31, 2023 17:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in the Wells Fargo Healthcare Conference

ROCKVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
August 21, 2023 09:00 ET | Source: Supernus Pharmaceuticals, Inc.

Bethany L. Sensenig Joins Supernus’ Board of Directors

ROCKVILLE, Md., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...